First, glutaminolysis [59] could be targeted by glutaminase inhibitors, such as the small inhibitor CB-839, that already showed promising results in resistant myeloma [60], esophageal carcinoma [61], and ovarian cancer [62]. Here, GLS is linked to ovarian carcinoma.